“Neumora Therapeutics reported positive Phase 1b results for NMRA-511, an oral vasopressin 1a receptor antagonist, showing clinically meaningful reductions in agitation symptoms among Alzheimer’s disease patients. The drug achieved a 15.7-point mean reduction on the Cohen-Mansfield Agitation Inventory (CMAI) total score, with even stronger effects in patients with elevated baseline anxiety, including up to a 20.1-point CMAI reduction in subgroup analyses. NMRA-511 exhibited excellent tolerability with no sedation or somnolence, supporting plans to explore higher doses through a multiple ascending dose expansion in 2026, alongside extended-release formulation work for potential once-daily dosing.”
Detailed Clinical Progress and Forward Path for NMRA-511
Neumora Therapeutics has advanced its neuroscience pipeline with encouraging early-stage data from NMRA-511, positioning the candidate as a potential new option for one of the most challenging aspects of Alzheimer’s disease: agitation. This behavioral symptom affects a significant portion of patients with Alzheimer’s dementia, often leading to increased caregiver burden, institutionalization, and reduced quality of life. Current treatments remain limited, with only one FDA-approved medication specifically indicated for agitation in Alzheimer’s—brexpiprazole—leaving substantial unmet need for therapies that are effective without causing excessive sedation or other tolerability issues.
The Phase 1b signal-seeking study evaluated NMRA-511 in adults aged 55-90 with mild to severe dementia (Mini-Mental State Examination scores of 5-24) and clinically significant agitation (baseline CMAI total scores of 45-100). The trial included a modified analysis set of 71 patients receiving twice-daily 20 mg NMRA-511 or placebo over an eight-week evaluation period. While the study was not powered for statistical significance, it successfully met its goal of detecting a clinical signal.
Key efficacy findings centered on the Cohen-Mansfield Agitation Inventory (CMAI), a widely used 29-item scale assessing agitated behaviors across categories such as aggressive, physically non-aggressive, and verbally agitated actions. NMRA-511 produced a mean 15.7-point reduction from baseline on the CMAI total score, which represents a clinically meaningful improvement in agitation severity. Placebo-adjusted reductions were 2.6 points at week six and 2.1 points at week eight in the overall population.
The most compelling results emerged in a prespecified subgroup of patients with elevated baseline anxiety, as measured by the Rating Anxiety in Dementia (RAID) scale (score ≥11). This group, comprising about half the participants, showed heightened responses:
Placebo-adjusted CMAI total score reductions of 7.6 points at week six and 5.6 points at week eight.
In some analyses, absolute CMAI reductions reached approximately 20.1 points in the elevated-anxiety subgroup.
Cohen’s d effect sizes ranged from 0.51 to 0.64 on CMAI in this subgroup, described as unsurpassed compared to benchmarks from approved therapies.
Stronger signals on secondary measures, including Clinical Global Impression-Severity (CGI-S) for agitation (effect sizes up to 0.78) and Neuropsychiatric Inventory (NPI) agitation/aggression domain (effect sizes 0.42–0.46), with nominal p-values as low as <0.05.
These outcomes highlight NMRA-511’s potential differentiation, particularly in patients where anxiety contributes to agitation early in the disease course. Anxiety often precedes or co-occurs with agitation, and addressing both could offer broader symptom relief.
Safety data further bolster the program’s outlook. NMRA-511 demonstrated a favorable profile, with treatment-emergent adverse events generally mild to moderate. No instances of somnolence or sedation were reported—a key advantage over many existing antipsychotics or sedating agents used off-label for agitation. Discontinuation rates due to adverse events stood at 2.5%, and one serious adverse event occurred but fully resolved.
Building on this tolerability, Neumora plans targeted next steps in 2026:
Initiation of a multiple ascending dose (MAD) expansion cohort to evaluate higher doses of NMRA-511, aiming to optimize exposure and potentially amplify efficacy.
Formulation development for an extended-release version to support once-daily dosing, which could improve patient adherence and convenience.
These efforts will inform future dose-ranging studies, potentially leading to a Phase 2/3 program. The company also anticipates enriching future trials for patients with elevated anxiety to maximize the observed signal.
NMRA-511’s mechanism as a highly potent, brain-penetrant, selective vasopressin 1a receptor (V1aR) antagonist targets a novel pathway in neuropsychiatric symptoms. Vasopressin modulation has shown promise in modulating social and emotional behaviors, and this approach could provide a non-sedating alternative in Alzheimer’s agitation management.
Overall, the Phase 1b results mark a meaningful step forward for Neumora’s efforts in neurodegenerative and neuropsychiatric disorders. With agitation affecting millions globally and limited tolerable options available, NMRA-511’s early profile offers hope for improved outcomes in this underserved area.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, medical advice, or a recommendation to buy or sell any securities. The information presented is based on publicly available data and should not be relied upon as the sole basis for investment or treatment decisions.